Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T15:07:02.237Z.
Consensus retrieved: 2026-10-06T12:27:12.210Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T15:07:02.237Z.
Quote observation: 2026-10-06T15:05:10.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 7de6214b49539a8b367d6f361c7a4ef799fc80225bf39e2c2ad4211b42324921
Forward PE Ratio (N/A) = Dated Quote Price ($30.13) / Consensus Forward EPS ($-0.08)
FORWARD PE RATIO
N/A
Harrow Health, Inc.
Market Cap
$1.12B
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Harrow Health, Inc. (HROW) | $1.12B | N/A |
| Amphastar Pharmaceuticals, Inc. (AMPH)vs › | $1.12B | 8.56 |
| Damora Therapeutics, Inc. (DMRA)vs › | $1.14B | N/A |
| OPKO Health, Inc. (OPK)vs › | $1.15B | N/A |
| Bicara Therapeutics Inc. Common Stock (BCAX)vs › | $1.09B | N/A |
| GoodRx Holdings, Inc. (GDRX)vs › | $1.16B | N/A |
| Avalyn Pharma Inc. Common Stock (AVLN)vs › | $1.16B | N/A |
| IRadimed Corporation (IRMD)vs › | $1.08B | 40.09 |
| Nektar Therapeutics (NKTR)vs › | $1.18B | N/A |
| Cullinan Therapeutics, Inc. (CGEM)vs › | $1.06B | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $30.13, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-0.08 | $-0.13 – $-0.02 | 5 | n/m |
| 2027-12-31 | $2.20 | $0.89 – $3.13 | 6 | 13.7x |
| 2028-12-31 | $3.94 | $2.72 – $5.27 | 4 | 7.6x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
